Cancer Cachexia Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The cancer cachexia market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $ 2.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.
The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives. Major trends in the forecast period include increasing research and development efforts, expanding therapeutic options, improved diagnosis rates, adoption of novel treatment modalities, and advancements in supportive care strategies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report
Scope Of Cancer Cachexia MarketThe Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Cancer Cachexia Market Overview
Market Drivers –
The increasing prevalence of cancer is expected to propel the growth of the cancer cachexia market going forward. Cancer refers to a condition where abnormal cells proliferate uncontrollably in the body, forming tumors and disrupting normal bodily processes. The cases of cancer is attributed to various factors, including lifestyle changes, environmental factors, an aging population, genetic predisposition, improved diagnostic methods leading to earlier detection, and increased awareness, prompting more people to seek medical attention. Advancements in medical technology and a greater understanding of cancer and its complications are resulting in more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are improving their ability to identify cachexia symptoms, facilitating earlier interventions and treatment commencement. For instance, in December 2023, according to the Australian Bureau of Statistics, an Australia-based government agency for national statistics, roughly 1.8% of the population, or 456,200 individuals, were reported to have cancer in Australia in 2022. Furthermore, in December 2021, according to the Australian Institute of Health and Welfare, an Australia-based government agency for health and welfare, approximately 151,000 Australians received a cancer diagnosis, equating to around 413 diagnoses per day in 2021. Therefore, the increasing prevalence of cancer is driving the growth of the cancer cachexia market.
Market Trends –
Major companies operating in the cancer cachexia market are developing innovative medication, such as ghrelin receptor agonists, to address the debilitating symptoms and complications associated with cachexia, aiming to improve patient outcomes and quality of life. A ghrelin receptor refers to a medication that activates the ghrelin receptor in the body, specifically aimed at addressing cancer cachexia. For instance, in April 2021, Helsinn, a Switzerland-based pharmaceutical company, launched Adlumiz (anamorelin) in Japan for treating cancer cachexia in various cancers. Adlumiz (anamorelin) is a medication designed as a ghrelin receptor agonist to address cancer cachexia in various malignant tumors, including non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. Japanese health authorities approve Adlumiz, which has shown effectiveness in increasing body weight, muscle mass, and appetite in cancer cachexia patients. Anamorelin is a selective ghrelin receptor agonist which stimulates pathways to positively regulate body weight, muscle mass, appetite, and metabolism. The anticipated benefits of Adlumiz outweigh the identified risks, providing a promising option for adult cancer patients experiencing cachexia symptoms.
The cancer cachexia market covered in this report is segmented –
1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies
Get an inside scoop of the cancer cachexia market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp
Regional Insights –
North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.
Table of Contents
1. Executive Summary2. Cancer Cachexia Market Report Structure3. Cancer Cachexia Market Trends And Strategies4. Cancer Cachexia Market – Macro Economic Scenario5. Cancer Cachexia Market Size And Growth…..27. Cancer Cachexia Market Competitor Landscape And Company Profiles28. Key Mergers And Acquisitions
- Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
